Skip to main content
NCBI home page
Discover Oncology logoLink to Discover Oncology
. 2025 Nov 7;16:2056. doi: 10.1007/s12672-025-03922-0

iRGD-modified co-loaded curcumin piperine liposomes inhibit angiogenesis in non-small cell lung cancer through the VEGFR2/P38/MK2 signaling axis

Xunhua Huang 1,#, Yongzhong Chen 1,#, Jiayuan Chen 1, Jinkun Lin 1, Yixue Zhuang 1, Meixia Huang 1, Hongmin Yu 1, Mingfei Wang 1, Yingzheng Wang 1,✉, Yinghao Wang 1,✉
PMCID: PMC12595176  PMID: 41201753

Abstract

Background

In our previous study, we provided evidence that iRGD-modified co-loaded curcumin piperine liposomes (iRGD-LP-CUR-PIP) have in vitro and in vivo anti-non-small cell lung cancer (NSCLC) activity. However, the mechanism of action of CUR-PIP on NSCLC is unclear; therefore, this study aimed to investigate the mechanism of CUR-PIP combination anti-tumor therapy by inhibiting angiogenesis.

Methods

The target binding effect of iRGD on the integrin avβ3 receptor was observed by cellular uptake assay. Western blot (WB) and immunofluorescence analyses were performed to investigate the effect of iRGD-LP-CUR-PIP on the VEGFR2/P38/MK2 pathway in vivo. In addition, a new A549 + HUVEC co cultured cell model was established and characterized for migration analysis.WB and immunofluorescence were used to detect the effect of iRGD-LP-CUR-PIP on the VEGFR2/P38/MK2 pathway in vitro, and the effect of iRGD-LP-CUR-PIP on the VEGFR2/P38/MK2 pathway was verified by constructing plasmids transfected to knock down VEGFR2 expression.

Results

Our data showed that iRGD-LP could bind to the αvβ3 receptor on the cell membrane surface; with increasing uptake time, A549 cells could easily enter. The results of in vitro and in vivo mechanism experiments showed that iRGD-LP-CUR-PIP and iRGD-LP-CUR both reduced the levels of VEGF and VEGFR2 proteins. However, for downstream proteins (p-P38MAPK and p-MK2), iRGD-LP-CUR-PIP was more effective in reducing protein levels than iRGD-LP-CUR. In addition, VEGFR2 silencing almost completely inhibited the phosphorylation of P38 and MK2, while iRGD-LP-CUR-PIP did not enhance the inhibition of P38 and MK2 phosphorylation after VEGFR2 silencing.

Conclusion

iRGD-LP-CUR-PIP reduces tumor angiogenesis and affects tumor growth by inhibiting the VEGFR2/P38/MK2 pathway. Among them, CUR affects VEGF and PIP may affect CTR1, which in turn affects CTR1-VEGFR2 co-internalization and downstream signaling pathways. These changes result in enhanced anti-tumor activity by CUR-PIP binding, and the best anti-tumor activity was observed in the iRGD-LP-CUR-PIP group compared with the other groups.

Supplementary Information

The online version contains supplementary material available at 10.1007/s12672-025-03922-0.

Keywords: Angiogenesis, iRGD, Curcumin, Piperine, Targeted nanodrug delivery, VEGF

Introduction

Lung cancer is the second most common cancer in the world, with high incidence and mortality rates [1]. The World Health Organization divides lung cancer into two major categories; non-small cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancer cases [2–4]. Chemotherapy is effective in NSCLC but has unavoidable toxicities and side effects [5, 6]. Numerous studies have shown that combination therapy has enormous potential value in treating lung cancer. The combination of targeted or chemotherapy drugs with natural compounds may improve the efficacy of drug therapy and reduce adverse reactions [7]. The anti-cancer properties of curcumin (CUR) are currently a research hotspot [8, 9], but its chemical properties are unstable [10, 11]. The combination of piperine (PIP) and CUR can improve its bioavailability [12]. Therefore, our research group successfully prepared liposomes containing iRGD-LP-CUR-PIP in the early stage, and we evaluated and validated their anti-tumor efficacy via in vitro and in vivo experiments [13]. However, the mechanism of their action is unclear, and further exploration is needed to clarify their roles.

The growth of tumors relies on abundant blood vessels to provide nutrients, and abnormal angiogenesis is a key factor in tumor progression.As one of the most effective vascular growth factors, vascular endothelial growth factor (VEGF) [14]. These VEGFs bind to VEGF receptors (VEGFRs, including VEGFR-1-3) and neurokinins (neurokinin-1 and − 2), leading to self-phosphorylation of tyrosine residues in these receptors, which can subsequently activate cellular substances such as members of the mitogen-activated protein kinase (MAPK) superfamily, thereby regulating vascular endothelial cell proliferation, differentiation, and survival [15, 16]. Natural compounds play an important role in regulating tumor angiogenesis through VEGF [17], such as CUR, resveratrol, green tea polyphenols, and PIP can synergistically act with VEGF/VEGFR2 inhibitors to enhance their anti-angiogenic effects [18]. Thus, blocking-up the VEGF/VEGFR2 signaling pathway can effectively curb tumor angiogenes.

The tumor-targeting lipid system, utilizing iRGD peptides to modify natural compounds, offers a highly promising drug delivery system [19–21]. Therefore, iRGD coupling and combined anti-angiogenic natural products can enhance the active targeting effect on tumor angiogenesis and reduce toxic side effects. In our previous study, we successfully constructed iRGD-LP-CUR-PIP and verified in vitro and in vivo that it had anti-NSCLC activity. However, the mechanism of action of CUR-PIP on NSCLC is unknown. In this study, we found that iRGD peptide surface-modified liposomes effectively enhanced uptake and anti-angiogenic activity of A549 tumor cells. Mechanism studies have shown that iRGD-LP-CUR-PIP inhibits tumor endothelial cell proliferation and differentiation by inhibiting the VEGFR2/P38/MK2 signaling axis, thereby inhibiting neovascularization. In addition, iRGD-LP-CUR-PIP inhibits the growth and angiogenesis of A549 tumors in nude mice by downregulating VEGFR2/P38/MK2.

Materials and methods

Materials

The reagents used for preparing liposomes have been indicated in the published articles of this project [13]. VEGF rabbit mAb, VEGFR2 rabbit mAb, TEM1 mouse mAb, TEM8 mouse mAb, P38 MAPK polyclonal antibody rabbit mAb, phospho-P38 MAPK rabbit mAb, MAPKAPK2 polyclonal antibody, phospho-MAPKAPK2 rabbit mAb, HSP27 rabbit mAb, and CTR1 rabbit mAb were used in this study.

Cells and animals

The A549 and human umbilical vein endothelial cell (HUVEC) lines were obtained from the Chinese Academy of Sciences Stem Cell Bank (Shanghai, China). Male BALB (Bagg Albino)/c nude mice, were provided by the Experimental Animal Center of Fujian University of Traditional Chinese Medicine (Fuzhou, China), grant number: FJTCM IACUC 2022063).

Preparation of iRGD-LP-CUR-PIP

iRGD-LP-CUR-PIP was prepared by thin-film hydration. In our previous study, We optimized the formulation parameters by single factor test and Box-Behnken design combined with response surface methodology, and morphology was observed by transmission electron microscopy. The release characteristics of iRGD-LP-CUR-PIP in vitro were investigated by membrane dialysis [13].

Western blotting

The protein concentrations were measured by a BCA Protein Assay Kit (Thermo Fisher Scientific, USA) and denatured at 100 °C for 10 min. Approximately 50 µg of protein was separated by 10% SDS-PAGE and then transferred to PVDF membranes (Millipore, USA). After incubation with the specified primary antibodies for 12 h at 4 °C and secondary antibodies for 60 min at room temperature, the membranes were washed three times with TBST. The blots were visualized using a two-color infrared imaging system (Odyssey, USA). Expression levels of proteins included VEGF (1 : 2000, 19003-1-AP, Proteintech), VEGFR2 (1:5000, 26415-1-AP, Proteintech), Integrin Alpha V + Beta3 (1 : 1000, bs-1310R, Bioss), TEM8 (1:1000, 15091-1-AP, Proteintech), TEM1 (1:2000, 60170-1-lg, Proteintech), MK2 (1:1000, 13949-1-AP, Proteintech), p-MK2 (1:1000, BS4902, Bioword), HSP27 (1:1000, 50353, Cell Signaling), P38 (1:1000, 14064-1-AP, Cell Proteintech), p-P38 (1:1000, AF4001, Proteintech), GAPDH (1:1000, 2118, CST), and CTR1 (1:1000, 16023-H02H, Sino Biological). These proteins were normalized to GAPDH expression. In the experiment, after successful transfer, we trimmed the desired band of interest based on the molecular weight of the antibody. We confirm that no image processing operations (such as stitching, erasing, or selective enhancement) have been performed other than uniform cropping and brightness/contrast adjustments for the entire image using Image Lab software.

Cellular uptake

We inoculated A549 cells into a cell culture dish (5 × 104 cells/culture dish). The cells were co-incubated with fluorescent iodide (DiR)-labeled solution, DiR-labeled LP, or DiR-labeled iRGD-LP for 2 h and washed twice with PBS [22]. Fixed with 4% paraformaldehyde for 10 min, washed with PBS, and stained with anti fluorescence quencher containing DAPI for 10 min, the cell uptake of different treatment groups was observed by using a confocal laser scanning microscope. All measurements were repeated three times.

Co-culturing system

In short, the cell co-culture model involved co-culturing HUVEC and A549 in a Transwell chamber co-culture system containing matrix gel, providing a tumor microenvironment for the growth of HCVECs and inducing their transformation into tumor-derived endothelial cells (Td-ECs). The specific steps were as follows: A549 cell suspension with a density of 1 × 104/mL was prepared and inoculated in the upper chamber to prepare 1 × 105/mL HUVECs, which were inoculated into the lower lumen. The culture was continued every 24 h to form monolayer cells in a subfusion state (80%–90%) [23]. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were performed to identify changes in cell characteristics under co-culture conditions to determine whether the co-culture model was successfully constructed. At the same time, HUVECs cultured separately were used as control cells, and their inoculation density, culture conditions, and time were the same as those of co-cultured cells.

Cell migration assays

We inoculated Td-ECs at 6 × 105cell/well in a 6-well plate, which was incubated at 37 °C for 24 h. We then scraped three lines with a 200 µL pipette tip for each well and washed them with PBS three times. Subsequently, different drugs were added to various wells for 24 h, each with a volume of 10–60 µL. The control group was added with 60 µL of culture medium. At 0 and 24 h, the width was captured using a Nikon eclipse Ti-S Microscope. The anti-migration effect of treatment groups was evaluated by the percentage of gap closure, which was calculated according to the following formula:

graphic file with name 12672_2025_3922_Article_Equa.gif

Immunofluorescence analysis

Fix tumor tissue with 4% paraformaldehyde, then slice and detect protein fluorescence intensity using CD31, VEGF, and VEGFR2 antibodies. Inoculate Td-ECs into a cell culture dish containing 5 × 104 cells/dish, incubate with the drug containing formula for 24 h, and incubate at room temperature for 1.5 h using fixation, permeabilization, blocking, VEGF primary antibody binding, and secondary antibody. Add 10–20 µL of DAPI dropwise and stain in the dark for 10 min. All samples are observed under a fluorescence microscope (LEICA, USA).

Molecular docking verification between the core substances and key targets

Download and screen the three-dimensional structure of PIP active compounds through pubchem, find the corresponding protein ID in uniport, search for the pdb format of the corresponding structure in PDB, and use PyMol software to remove water molecules and existing ligands from the receptor. Finally, molecular docking was performed using MOE 2019 software, and < − 5.0 kcal/mol suggested strong binding activity [24].

Plasmid construction and transfection

To silence VEGFR2 in Td-ECs, we cloned VEGFR2-shRNA (NM_002253.2) into the VB191 vector (APExBIO, Shanghai, China). For transient knockdown studies, VEGFR2-shRNA and control shRNA (sh-NC) plasmids were transfected for 24 h using Lipo 3000™ reagent (ThermoFisher, L3000015, USA).

Statistical analysis

Statistical analysis was performed using Prism 8.0 (GraphPad). All experimental data were shown by mean ± standard deviation (SD). For comparisons between two groups, a two-tailed Student’s t test was applied. For comparisons among multiple groups, one-way analysis of variance (ANOVA) was used and statistical significance was set at P < 0.05.

Results

iRGD-LP-CUR-PIP May inhibit tumor angiogenesis via the VEGFR2/P38/MK2 pathway

In this study, the mechanism of action of iRGD-LP-CUR-PIP on the tumors of A549 tumor-bearing nude mice was investigated (Fig. 1A). We measured the anti-angiogenesis effects by using immunofluorescence of CD31, which is an endothelial marker that allows us to quantify vessels. Our results showed that iRGD-LP-CUR-PIP had a significantly decreasing effect on vascular density as measured by CD31 in tumor mice (Fig. 1B and C). The average fluorescence intensity of VEGF and VEGFR2 in the tumor tissues was detected using immunofluorescence. We observed that iRGD-LP-CUR-PIP could effectively reduce the fluorescence expression intensity of VEGF and VEGFR2 in the tumor tissues of A549 hormonal nude mice (Fig. 1D and F). WB confirmed that iRGD-LP-CUR-PIP reduced the protein expression of VEGF and VEGFR2 in tumor tissue (Fig. 1E and G). The VEGF-VEGFR2 signaling axis could regulate phosphorylation activation of p38 MAPK. Mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2 or MK2), the downstream substrate of p38 MAPK, governs the activation and deactivation of heat shock protein 27 (HSP27). A previous study reported that the activation of the p38MAPK/MK2/HSP27 axis promotes angiogenesis [25]. In this study, we found that iRGD-LP-CUR-PIP inhibited the expression of p-P38, p-MK2, and HSP27 in tumor tissues (Fig. 1H and J). Interestingly, iRGD-LP-CUR-PIP and iRGD-LP-CUR decreased VEGF and VEGFR2 protein levels equally. However, for the phosphorylation of downstream proteins (p-P38 and p-MK2), iRGD-LP-CUR-PIP decreased protein levels more than iRGD-LP-CUR. In summary, iRGD-LP-CUR-PIP inhibited NSCLC angiogenesis, and its anti-tumor effects may be related to downregulating the VEGFR2/P38/MK2 signaling pathway.

Fig. 1.

Fig. 1

Open in a new tab

iRGD-LP-CUR-PIP affects tumor growth through the VEGF/P38/MK2 pathway (n = 4). Notes: A Schematic of the mechanism of iRGD LP CUR-PIP combined therapy for A549 tumor-bearing nude mice. B Fluorescence of CD31 protein in tumors of A549 hormonal nude mice by iRGD-LP-CUR-PIP. C Quantification of fluorescence intensity for CD31. D F Fluorescence of VEGF and VEGFR2 protein in tumors of A549 hormonal nude mice by iRGD-LP-CUR-PIP. E, G–J The effect of iRGD LP CUR-PIP on the secretion of VEGF, VEGFR2, p-P38, P38, p-MK2, MK2 and HSP27 proteins in A549 tumor tissues of nude mice was determined using Western Blot method. Versus the control group: *P < 0.05, **P < 0.01, ***P < 0.001, versus the LP-CUR-PIP group: #P < 0.05, versus the iRGD-LP-CUR group: &P < 0.05, &&P < 0.01

iRGD-LP-CUR-PIP targets tumor cells

To determine the uptake of LP by cells, we incubated A549 with different DiR-labeled liposome formulations for 2 h. We used DiR (red fluorescence) to track the cell distribution of LP and DAPI (blue fluorescence) to stain the nucleus. As shown in Fig. 2A and B, tumor cells treated with non-targeted LP showed weak red fluorescence. To support RGD integrin αvβ3, we co-treated free iRGD (fiRGD) and iRGD-LP into A549 cells to investigate their interactions during iRGD-LP uptake. Figure 2C and D show the competitive combination of fiRGD and iRGD-LP αvβ3. At elevated concentrations of fiRGD, the uptake of iRGD-LP decreased accordingly. Overall, iRGD-LP could be effectively absorbed by A549 cells, which is of great significance for delivering natural products of anti-lung cancer effects into cells.

Fig. 2.

Fig. 2

Open in a new tab

Cell uptake of iRGD-Lip prepared from A549 cells (n = 3). A The uptake of DiR-labeled LP, DiR-labeled iRGD-LP, and DiR-labeled non LP (No LP) by A549 cells for 2 h. Red and blue fluorescence represent DiR and DAPI, respectively, and the image was captured in ×400 magnification. B Quantification of DiR fluorescence intensity in LP- and iRGD-LP-treated cells versus the LP-DiR group: ***P < 0.001. C Co-therapy with intake of iRGD-LP and free iRGD (fiRGD). The competitive binding of fiRGD inhibits the uptake of iRGD-LP into A549 cells. D Quantification of fluorescence intensity for ανβ3 and iRGD-LP-DiR in C versus the none group: ***P < 0.001 versus the fiRGD (2 µg) group: #P < 0.05

iRGD-LP-CUR-PIP reduced VEGF in Td-ECs

The above results indicated that iRGD-LP-CUR-PIP inhibited angiogenesis and had a targeted effect on tumor cells. When we used HUVECs for administration, we found that iRGD-LP-CUR-PIP had no effect on the generation of VEGF in HUVECs (Fig. 3A). Therefore, Td-ECs were prepared using Transwell cells to construct a co-culture system of A549 and HUVECs. Compared with HUVECs, Td-ECs underwent a series of ultrastructural changes. SEM results showed that the elongation of Td-ECs was reduced while the filamentous pseudopods on the cell ends became few and short, which indicated that the cells were in an active state and suitable for migration (Fig. 3B). TEM results showed that Td-ECs exhibited more vesicular structures and obvious mitochondrial vacuolization than the other cells (Fig. 3C). WB results showed that Td-ECs highly expressed tumor endothelial cell-specific antigens TEM1 and TEM8 (Fig. 3D and G). We observed that iRGD-LP-CUR-PIP effectively reduced the expression of VEGF in Td-ECs by immunofluorescence and WB (Fig. 3H and J). Therefore, iRGD-LP-CUR-PIP was effective on tumor endothelial cells without affecting normal endothelial cells. Blood vessels present in a specific tumor are actually embedded blood vessels composed of endothelial cells and tumor cells, which are interdependent. Therefore, targeting tumor blood vessels is closely aligned to the internal environment of the organism, cutting off the nutritional supply of the tumor by inhibiting tumor angiogenesis, rendering it unable to continue growing and ultimately achieving tumor inhibition.

Fig. 3.

Fig. 3

Open in a new tab

Characteristics of the co-cultivation system model (n = 3) A Changes in VEGF protein expression levels in HUVECs were detected by Western blot. B Observation of cell ultrastructure of Td-ECs obtained from co-culture of A549 and HUVECs by SEM. C Observation of cell ultrastructure of Td-ECs obtained from co-culture of A549 and HUVECs by TEM. D–E Detection of tumor endothelial cell specific antigen TEM1 and TEM8 by Western blot. F–G The expression levels of TEM1 and TEM8 proteins were quantitatively compared with those in the HUVEC group, **P < 0.01,*P < 0.05. H Fluorescence of VEGF protein in Td-ECs by iRGD-LP-CUR-PIP. I Quantification of fluorescence intensity for VEGF in H versus the control group: **P < 0.01, vs. LP-CUR-PIP group: ##P < 0.01. J. Changes in VEGF protein expression levels in Td-ECs were detected by Western blot, versus the control group: **P < 0.01, versus the LP-CUR-PIP group: #P < 0.05

iRGD-LP-CUR-PIP downregulated VEGFR2 and inhibited phosphorylation of P38 and MK2 in vitro

To further specify the anti-angiogenesis effects of iRGD-LP-CUR-PIP in vitro, we conducted cell migration experiments on Td-ECs co-cultured with A549/HUVECs. In the cell migration experiments, compared with the control group, different liposomes containing CUR all had larger wound areas, with iRGD-LP-CUR-PIP being more significant, indicating a greater anti-migration effect. The migration rates of co-cultured cells treated with iRGD-LP-CUR and iRGD-LP-CUR were 12.4% and 13.4%, respectively, which were much lower than those of LP-CUR-PIP (18.6%) and control group (25.4%) (Fig. 4A and B). Signaling pathway proteins of Td-ECs were detected by WB (Fig. 4C and F). iRGD-LP-CUR-PIP reduced the protein expression of VEGFR2, inhibited the phosphorylation of P38 and MK2, and downregulated HSP27. In addition, treatment with iRGD modification had better pharmacological effects than other groups. Similarly, in vivo, for VEGF and VEGFR2, iRGD-LP-CUR-PIP and iRGD-LP-CUR decreased protein levels equally. However, for the phosphorylation of downstream proteins (p-P38 and p-MK2), iRGD-LP-CUR-PIP decreased protein levels more than iRGD-LP-CUR.

Fig. 4.

Fig. 4

Open in a new tab

iRGD-LP-CUR-PIP affects tumor angiogenesis through the VEGFR2/P38/MK2 signaling pathway. A, B Effect of iRGD-LP-CUR-PIP on the migration of Td-ECs (100×; n = 3). C–F The effect of iRGD LP CUR-PIP on the secretion of VEGFR2, p-P38, P38, p-MK2, MK2 and HSP27 proteins by Td-ECs was determined using Western Blot method Effect and its quantitative analysis (n = 4). Versus the control group, *P < 0.05, **P < 0.05, ***P < 0.001; versus the LP-CUR-PIP group, #P < 0.05,###P < 0.001, versus the iRGD-LP-CUR group, &P < 0.05

PIP inhibited CTR1 to affect the downstream signaling pathway of VEGFR2

We found that the iRGD-LP-CUR-PIP group and iRGD-LP-CUR group could significantly downregulate the expression of VEGF and VEGFR2 proteins equally. However, for the expression of downstream phosphorylation, the difference between the two groups was obvious. Copper transport 1 (CTR1) participated in VEGFR2 signaling transduction. Upon VEGF stimulation, CTR1 is rapidly sulfonylated at the cytoplasmic C-terminus of Cys189, which induces the formation of the CTR1-VEGFR2 disulfide bond and co-internalization with early nuclear endosomes, driving sustained VEGFR2 signaling and stimulating downstream phosphorylation secretion, enhancing tumor angiogenesis [26] (Fig. 5D). To further investigate the potential binding interactions of PIP and CTR1, we performed molecular docking analysis to assess the binding affinity of PIP to CTR1. The molecular docking score (kcal/mol− 1) was used to show the binding strength. In our results, all of the binding energies were below − 4.0 kJ mol− 1, and these results indicated that CUR had very strong binding activity to VEGF targets and PIP had moderate to strong binding activity to key CTR1 targets. The estimated docking binding energy was 5.7297 kcal/mol. In this conformation, the ligand mainly contacted the protein through hydrogen bonds. The ligand could form hydrogen bonds with the N atom of the Asn 104 side chain of the protein, which was conjugated with the side chain hydrocarbon atom XingchengCH benzene ring of Ile101 (Fig. 5A). The results of ex vivo WB showed that the addition of PIP significantly increased the inhibitory effect of liposome drugs on CTR1 in vivo and vitro (Fig. 5B and C). Thus, PIP may affect the downstream signaling pathway of VEGFR2 by inhibiting CTR1.

Fig. 5.

Fig. 5

Open in a new tab

iRGD-LP-CUR-PIP may affect the VEGFR2/P38/MK2 signaling pathway by influencing CTR1 cysteine oxidation (n = 3). A Schematic of molecular docking of piperine. B Effect of iRGD-LP-CUR-PIP on tumor tissue + secretion of CTR1 protein and its quantitative analysis (n = 3). C Effect of iRGD-LP-CUR-PIP on CTR1 protein secretion by Td-ECs and its quantitative analysis (n = 3). D Schematic of the mechanism of interaction between CTR1 and VEGF versus the control group, *P < 0.05, ***P < 0.001; versus the LP-CUR-PIP group, #P < 0.05,##P < 0.01,###P < 0.001; versus the iRGD-LP-CUR group, &P < 0.05, &&&P < 0.001

Effect of iRGD-LP-CUR-PIP treatment and VEGFR2 silencing alone and in combination on VEGFR2/P38/MK2 signaling in Td-ECs.

Knockdown of VEGFR2 expression by ShRNA to block the downstream signaling pathway of VEGFR2 further validated that iRGD-LP-CUR-PIP inhibited tumor angiogenesis through the VEGFR2/P38/MK2 signaling pathway. The results were as follows: the shRNA-VEGFR2 silencing plasmid was constructed (Fig. 6A), and the results verified by WB showed that the silencing plasmid significantly inhibited the expression of VEGFR2 in Td-ECs compared with the control group at 24 h post-transfection. We chose this plasmid for the cell experiments (Fig. 6B). Given that iRGD-LP-CUR-PIP treatment of Td-ECs inhibited VEGF signaling, we asked whether such effects of iRGD-LP-CUR-PIP would be abrogated with silencing of VEGFR2. We observed that VEGFR2 silencing almost completely inhibited the phosphorylation of P38 and MAPK2, and the combination of iRGD-LP-CUR-PIP with VEGFR2 silencing did not augment the inhibition of the phosphorylation of P38 and MK2 (Fig. 6C and F). These observations proved the regulation of the iRGD-LP-CUR-PIP on the VEGFR2/P38/MK2 signaling pathway.

Fig. 6.

Fig. 6

Open in a new tab

Construction of VEGFR2 plasmid transfection (n = 3). A Construction of knockdown plasmid shRNA-VEGFR2-1 B The silencing expression of shRNA-VEGFR2-1 was verified by Western blot: C p-P38,P38 protein band and D p-MK2,MK2 protein band. E p-P38 relative expression. F p-MAPK2 protein relative expression versus the control group, *P < 0.05, ***P < 0.001

Discussion

iRGD is a tumor-targeting and tumor-penetrating peptide that binds with αν integrins. Our research results showed that A549 cells co-cultured with iRGD-LP exhibited strong red fluorescence, and they were clustered around the cell membrane. This result was attributed to the interaction between integrin αvβ3 on the cell surface and RGD on iRGD-LP, which reportedly occurs during the internalization of RGD ligands into cells through receptor-mediated endocytosis [27, 28]. In addition, when iRGD was co-administered with nanoformulations, the bystander effect of iRGD activated a large amount of drugs to be transported, which could improve the bioavailability and efficacy of drug delivery [29, 30]. In our previous study, we designed and prepared an iRGD-LP-CUR-PIP with iRGD as the functional targeting substrate, CUR and PIP as the model drugs, and LP as the delivery system. We verified its anti-NSCLC activity in vitro and in vivo, and we found that drugs with iRGD had good anti-tumor efficacy, and the combination of CUR and PIP was superior to CUR alone. However, its mechanism remains unclear.

To further investigate the inhibitory effect of iRGD-LP-CUR-PIP on tumor angiogenesis through the VEGFR2/P38/MK2 pathway, we used WB and immunofluorescence methods to validate the results in vivo. The results showed that iRGD-LP-CUR-PIP inhibited the expression of p-P38, p-MK2, and HSP27 in tumor tissue. Td-ECs were constructed in vitro, and their microstructure and specific antigens were detected using SEM, TEM, and WB. The results showed that tumor-induced phenotypic changes occurred in vascular endothelial cells, which was consistent with the current understanding of the interaction between tumor cells and vascular endothelial cells. Thus, we successfully constructed a co-culture model for preparing tumor endothelial cells. Unlike normal endothelial cells, tumor vascular endothelial cells are located in the tumor microenvironment, enhancing their ability to proliferate, migrate, and invade. Tumors and blood vessels are interdependent. Tumors provide vascular growth factors to endothelial cells, accelerating the occurrence and development of angiogenesis, whereas endothelial cells provide necessary nutrients for tumor proliferation and migration [31].Therefore, treating tumor blood vessels as targets must occur close to the growth environment within the body. By inhibiting the regeneration of tumor blood vessels, the nutritional supply to the tumor can be cut off, preventing its growth and achieving anti-tumor effects. The WB results further confirmed that iRGD-LP-CUR-PIP was effective on tumor endothelial cells without affecting normal endothelial cells.

An interesting finding in the validation of in vitro and in vivo mechanisms was that iRGD-LP-CUR-PIP and iRGD-LP-CUR both reduced VEGF and VEGFR2 protein levels. However, for downstream proteins (p-P38MAPK, p-MK2, and HSP27), iRGD-LP-CUR-PIP was more effective in reducing protein levels than iRGD-LP-CUR, and its anti-tumor effect may be related to the downregulation of the VEGFR2/P38/MK2 signaling pathway. According to reports, CTR1 is involved in VEGFR2 signaling transduction. Under VEGF stimulation, CTR1 rapidly undergoes sulfonylation at the cytoplasmic C-terminus of Cys189, inducing the formation of disulfide bonds between CTR1-VEGFR2 and co-internalizing with early endosomes, driving the sustained VEGFR2 signaling pathway and stimulating downstream phosphorylation secretion to enhance tumor angiogenesis [26]. Molecular docking results also confirmed that PIP may affect the downstream signaling pathway of VEGFR2 by inhibiting CTR1. In subsequent plasmid transfection experiments, we observed that VEGFR2 silencing almost completely inhibited the phosphorylation of P38 and MAPK2, whereas the binding of iRGD-LP-CUR-PIP to VEGFR2 silencing did not enhance the inhibition of P38 and MK2 phosphorylation. These observations further confirmed the regulatory effect of iRGD-LP-CUR-PIP on the VEGFR2/P38/MK2 signaling pathway.

Conclusion

The results of this study indicated that surface modification of iRGD peptides loaded with CUR-PIP could effectively enhance the cellular uptake and anti-angiogenic ability of Td-ECs. Research on its mechanism suggested that iRGD-LP-CUR-PIP inhibited angiogenesis by inhibiting the VEGF-VEGFR2 signaling axis and inducing cell migration in Td-ECs. In addition, iRGD-LP-CUR-PIP inhibited the growth and angiogenesis of A549 tumors in nude mice by downregulating VEGF-VEGFR2. Our research results indicated that using iRGD peptide-functionalized CUR-PIP as a carrier for anticancer drugs may be an efficient way to achieve tumor-targeted anti-angiogenic synergistic effects by eliminating pro-angiogenic signaling pathways.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary Material 1 (43.2MB, pptx)

Acknowledgements

The authors thank the Ministry of Science and Technology of Fujian Province for the financial.

support of the University-Industry-Research Cooperation Program.

Author contributions

Author 1 (HXH): Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing-Original Draft, Writing-Review & Editing;• Author 2(CYZ): Formal Analysis ;• Author 3 (CJY): Data Curation;• Author 4 (LJK): Data Curation;•Author 5 (ZYX): Conceptualization;•Author 6 (HMX): Software, Visualization;•Author 7 (YHM): Visualization;•Author 8(WMF): Investigation, Methodology, Software,•Author 9(WYZ)Conceptualization, Funding Acquisition, Resources, Supervision, Validation, Writing-Original Draft, Writing-Review & Editing;•Author 10(WYH)Conceptualization, Funding Acquisition, Resources, Supervision, Validation, Writing-Original Draft, Writing-Review & Editing;

Funding

This work was supported by the Ministry of Science and Technology of Fujian Province (Grant Number 2019N5010).

Data availability

Data is provided within the manuscript or supplementary information files.

Declarations

Ethics approval and consent to participate

This research was approved by the Committee on the Ethics of Animal Experiments of Fujian University of Traditional Chinese Medcine (Animal Protocol NO.FJTCM IACUC 2022063). The animal experiments in this study were conducted in accordance with the Basel Declaration. The maximal permitted tumor burden was defined as a volume ≤ 1,500 mm³ (or 15 mm diameter), consistent with institutional guidelines for humane endpoints. Throughout the study, no tumor exceeded this limit. Mice were monitored every 48 h; all were euthanized upon reaching ≤ 1,500 mm³ or if distress signs (e.g., weight loss > 20%, lethargy) occurred. No exceptions occurred.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xunhua Huang and Yongzhong Chen contributed equally to this work.

Contributor Information

Yingzheng Wang, Email: wangyingzheng@live.com.

Yinghao Wang, Email: wyhtcm@163.com.

References

  • 1.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. [DOI] [PubMed] [Google Scholar]
  • 2.Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 world health organization classification of tumors of the Lung, Pleura, Thymus, and heart. J Thorac Oncol. 2015;10(9):1240–2. [DOI] [PubMed] [Google Scholar]
  • 3.Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of Genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60. [DOI] [PubMed] [Google Scholar]
  • 4.Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: Non-Small cell lung Cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14(3):255–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ferrara R, Imbimbo M, Malouf R, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021;4(4):CD013257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced Non-small cell lung cancer and preexisting interstitial lung diseases: A systematic review and Meta-analysis. Chest. 2022;161(6):1675–86. [DOI] [PubMed] [Google Scholar]
  • 7.Pons-Fuster LE, Gomez GF, Lopez JP. Combination of 5-Florouracil and polyphenol EGCG exerts suppressive effects on oral cancer cells exposed to radiation. Arch Oral Biol. 2019;101:8–12. [DOI] [PubMed] [Google Scholar]
  • 8.Mundekkad D, Cho WC. Applications of Curcumin and its nanoforms in the treatment of cancer. Pharmaceutics 2023; 15(9). [DOI] [PMC free article] [PubMed]
  • 9.Kah G, Chandran R, Abrahamse H. Curcumin a natural phenol and its therapeutic role in cancer and photodynamic therapy: A review. Pharmaceutics 2023; 15(2). [DOI] [PMC free article] [PubMed]
  • 10.Kong D, Zhao Y, Men T, Teng CB. Hippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy. J Drug Target. 2015;23(2):125–33. [DOI] [PubMed] [Google Scholar]
  • 11.Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Erratum: Enhanced blood suspensibility and Laser-Activated Tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Erratum Theranostics. 2020;10(5):2401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yu KF, Zhang WQ, Luo LM, et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomed. 2013;8:2473–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang Y, Huang X, Chen H et al. The antitumour activity of a Curcumin and Piperine loaded iRGD-Modified liposome: in vitro and in vivo evaluation. Molecules 2023; 28(18). [DOI] [PMC free article] [PubMed]
  • 14.Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–86. [DOI] [PubMed] [Google Scholar]
  • 17.Fakhri S, Abbaszadeh F, Jorjani M, Pourgholami MH. The effects of anticancer medicinal herbs on vascular endothelial growth factor based on Pharmacological aspects: a review study. Nutr Cancer. 2021;73(1):1–15. [DOI] [PubMed] [Google Scholar]
  • 18.Lu X, Friedrich LJ, Efferth T. Natural products targeting tumor angiogenesis. Br J Pharmacol 2023. [DOI] [PubMed]
  • 19.Gao F, Zhang J, Fu C, et al. iRGD-modified lipid-polymer hybrid nanoparticles loaded with Isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. Int J Nanomed. 2017;12:4147–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Arya DK, Deshpande H, Kumar A et al. HER-2 receptor and alphavbeta3 integrin Dual-Ligand Surface-Functionalized liposome for metastatic breast cancer therapy. Pharmaceutics 2024; 16(9). [DOI] [PMC free article] [PubMed]
  • 21.Arya DK, Pandey P, Kumar A, et al. Dual-ligand functionalized liposomes with iRGD/trastuzumab co-loaded with gefitinib and Lycorine for enhanced metastatic breast cancer therapy. J Liposome Res. 2025;35(2):173–87. [DOI] [PubMed] [Google Scholar]
  • 22.Al FH, Choi ES, Kim JH, Kim E. Enhanced effect of autologous EVs delivering Paclitaxel in pancreatic cancer. J Control Release. 2022;347:330–46. [DOI] [PubMed] [Google Scholar]
  • 23.Lu S, Chen TT, Bie MJ, Wu JY, Xiong ZH. [Establishment of in vitro co-cultue system for tumor vascular endothelial cells]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013;44(2):308–12. [PubMed] [Google Scholar]
  • 24.Wang H, Li J, Gao Y, et al. Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl. 2010;12(4):535–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Xu Y, Jia Y, Wu N, Wang J, He L, Yang D. CD93 ameliorates diabetic wounds by promoting angiogenesis via the p38MAPK/MK2/HSP27 axis. Eur J Vasc Endovasc Surg. 2023;66(5):707–21. [DOI] [PubMed] [Google Scholar]
  • 26.Das A, Ash D, Fouda AY, et al. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis. Nat Cell Biol. 2022;24(1):35–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kemker I, Feiner RC, Muller KM, Sewald N. Size-Dependent cellular uptake of RGD peptides. ChemBioChem. 2020;21(4):496–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Nieberler M, Reuning U, Reichart F et al. Exploring the role of RGD-Recognizing integrins in cancer. Cancers (Basel) 2017; 9(9). [DOI] [PMC free article] [PubMed]
  • 29.Chen CY, Rao SS, Ren L, et al. Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis. Theranostics. 2018;8(6):1607–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G. New insights into therapeutic activity and anticancer properties of Curcumin. J Exp Pharmacol. 2017;9:31–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival. APMIS. 2004;112(7–8):431–40. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (43.2MB, pptx)

Data Availability Statement

Data is provided within the manuscript or supplementary information files.

Articles from Discover Oncology are provided here courtesy of Springer

RESOURCES